
Figure 1. Flow of participants through study



Antigen test: SARS-CoV-2 Antigen Test Card RT-PCR: Cepheid Xpert ® Xpress ® RT-PCR

Table 1. Participant characteristics (n=500)

Characteristics	All participants	
	n=500	
Gender, n (%)		
Male	158 (31.6)	
Female	342 (68.4)	
Age (years)		
Mean (SD)	51.4 (20.5)	
Range	18 - 98	
Age < 65, n (%)	370 (74.0)	
Age ≥ 65, n (%)	130 (26.0)	
Participant role, n (%)		
NHS staff	336 (67.2)	
NHS patients	164 (32.8)	
Symptoms		
Symptomatic	179 (35.8)	
Asymptomatic	321 (64.2)	
Ct values of RT-PCR positive samples, n (%)	195 (39.0)	
Ct < 25	102 (52.3)	
Ct 25 - 35	77 (39.5)	
Ct > 35	16 (8.2)	
SARS-CoV-2 Omicron sub-variants	195 (39.0)	
BA.1	22 (11.3)	
BA.2	67 (34.4)	
BA.5	57 (29.2)	
No lineage	49 (25.1)	

Table 3: Primary outcome measure - overall diagnostic performance of the MP Biomedicals antigen test

	NUMBER	SENSITIVITY %	SPECIFICITY %	ACCURACY %
	(%)	(95% CI)	(95% CI)	(95% CI)
TOTAL	500	80.0 (73.7 to 85.5)	100 (98.8 to 100)	92.2 (89.5 to 94.4)

Table 4: Secondary outcome measures - diagnostic performance of the MP Biomedicals antigen test in various categories **GENDER**

100

91.1

85.3

	(31.6)	(76.5 to 91.7)	(94.3 to 100)	(85.6 to 95.1)
FEMALES	342	75.0	100	92.7
	(68.4)	(65.3 to 83.1)	(98.5 to 100)	(89.4 to 95.2)
AGE				
AGE < 65 years	370	72.0	100	93.0
	(74.0)	(61.8 to 80.9)	(98.7 to 100)	(89.9 to 95.4)
AGE ≥ 65 years	130	87.3	100	90.0
	(26.0)	(79.2 to 93.0)	(87.7 to 100)	(83.5 to 94.6)
PARTICIPANT ROL	LE			
NHS STAFF	336	70.0	100	94.6
	(67.2)	(56.8 to 81.2)	(98.7 to 100)	(91.7 to 96.8)
NHS PATIENTS	164	84.4	100	87.2
	(32.8)	(77.2 to 90.1)	(88.1 to 100)	(81.1 to 91.9)
Ct VALUES				
PCR POSITIVES:	195			
CT < 25	102	98.0	-	-
	(52.3)	(93.1 to 99.8)		
CT 25 – 35	77	68.8	-	-
	(39.5)	(57.3 to 78.9)		
CT > 35	16	18.8	-	-
	(8.2)	(4.1 to 45.7)		
SYMPTOMATIC V	S ASYMPTOMATIC	•		
SYMPTOMATIC	179	82.2	100	88.3
		(74.1 to 88.6)	(94.1 to 100)	(82.6 to 92.6)
Days 0-3	132	80.0	100	87.1
	(73.7)	(69.9 to 87.9)	(92.5 to 100)	(80.2 to 92.3)
Days 4-7	35	100	100	100
		100	100	100
	(19.6)	(85.8 to 100)	(71.5 to 100)	(90.0 to 100)
Days 8-10				
Days 8-10	(19.6)	(85.8 to 100)	(71.5 to 100)	(90.0 to 100)
Days 8-10 Days 0-7	(19.6) 12	(85.8 to 100) 55.6	(71.5 to 100)	(90.0 to 100) 66.7
	(19.6) 12 (6.7)	(85.8 to 100) 55.6 (21.2 to 86.3)	(71.5 to 100) 100 (29.2 to 100)	(90.0 to 100) 66.7 (34.9 to 90.1)
	(19.6) 12 (6.7) 167	(85.8 to 100) 55.6 (21.2 to 86.3) 84.4	(71.5 to 100) 100 (29.2 to 100) 100	(90.0 to 100) 66.7 (34.9 to 90.1) 89.8
Days 0-7	(19.6) 12 (6.7) 167 (93.3)	(85.8 to 100) 55.6 (21.2 to 86.3) 84.4 (76.2 to 90.6)	(71.5 to 100) 100 (29.2 to 100) 100 (93.8 to 100)	(90.0 to 100) 66.7 (34.9 to 90.1) 89.8 (84.2 to 94.0)
Days 0-7	(19.6) 12 (6.7) 167 (93.3) 321	(85.8 to 100) 55.6 (21.2 to 86.3) 84.4 (76.2 to 90.6) 76.6	(71.5 to 100) 100 (29.2 to 100) 100 (93.8 to 100) 100	(90.0 to 100) 66.7 (34.9 to 90.1) 89.8 (84.2 to 94.0) 94.4
Days 0-7 ASYMPTOMATIC	(19.6) 12 (6.7) 167 (93.3) 321	(85.8 to 100) 55.6 (21.2 to 86.3) 84.4 (76.2 to 90.6) 76.6	(71.5 to 100) 100 (29.2 to 100) 100 (93.8 to 100) 100	(90.0 to 100) 66.7 (34.9 to 90.1) 89.8 (84.2 to 94.0) 94.4
Days 0-7 ASYMPTOMATIC SARS-CoV-2 Omic	(19.6) 12 (6.7) 167 (93.3) 321 ron sub-variants	(85.8 to 100) 55.6 (21.2 to 86.3) 84.4 (76.2 to 90.6) 76.6 (65.6 to 85.5)	(71.5 to 100) 100 (29.2 to 100) 100 (93.8 to 100) 100 (98.5 to 100)	(90.0 to 100) 66.7 (34.9 to 90.1) 89.8 (84.2 to 94.0) 94.4 (91.3 to 96.6)
Days 0-7 ASYMPTOMATIC SARS-CoV-2 Omic BA.1	(19.6) 12 (6.7) 167 (93.3) 321 ron sub-variants 22	(85.8 to 100) 55.6 (21.2 to 86.3) 84.4 (76.2 to 90.6) 76.6 (65.6 to 85.5)	(71.5 to 100) 100 (29.2 to 100) 100 (93.8 to 100) 100 (98.5 to 100)	(90.0 to 100) 66.7 (34.9 to 90.1) 89.8 (84.2 to 94.0) 94.4 (91.3 to 96.6)
Days 0-7 ASYMPTOMATIC SARS-CoV-2 Omic BA.1	(19.6) 12 (6.7) 167 (93.3) 321 ron sub-variants 22 (11.3)	(85.8 to 100) 55.6 (21.2 to 86.3) 84.4 (76.2 to 90.6) 76.6 (65.6 to 85.5) 72.7 (49.8 to 89.3)	(71.5 to 100) 100 (29.2 to 100) 100 (93.8 to 100) 100 (98.5 to 100)	(90.0 to 100) 66.7 (34.9 to 90.1) 89.8 (84.2 to 94.0) 94.4 (91.3 to 96.6)
Days 0-7 ASYMPTOMATIC SARS-CoV-2 Omic BA.1	(19.6) 12 (6.7) 167 (93.3) 321 ron sub-variants 22 (11.3) 67	(85.8 to 100) 55.6 (21.2 to 86.3) 84.4 (76.2 to 90.6) 76.6 (65.6 to 85.5) 72.7 (49.8 to 89.3) 86.6	(71.5 to 100) 100 (29.2 to 100) 100 (93.8 to 100) 100 (98.5 to 100)	(90.0 to 100) 66.7 (34.9 to 90.1) 89.8 (84.2 to 94.0) 94.4 (91.3 to 96.6)
Days 0-7 ASYMPTOMATIC SARS-CoV-2 Omic BA.1 BA.2	(19.6) 12 (6.7) 167 (93.3) 321 ron sub-variants 22 (11.3) 67 (34.4)	(85.8 to 100) 55.6 (21.2 to 86.3) 84.4 (76.2 to 90.6) 76.6 (65.6 to 85.5) 72.7 (49.8 to 89.3) 86.6 (76.6 to 93.7)	(71.5 to 100) 100 (29.2 to 100) 100 (93.8 to 100) 100 (98.5 to 100) -	(90.0 to 100) 66.7 (34.9 to 90.1) 89.8 (84.2 to 94.0) 94.4 (91.3 to 96.6)
Days 0-7 ASYMPTOMATIC SARS-CoV-2 Omic BA.1 BA.2	(19.6) 12 (6.7) 167 (93.3) 321 ron sub-variants 22 (11.3) 67 (34.4) 57	(85.8 to 100) 55.6 (21.2 to 86.3) 84.4 (76.2 to 90.6) 76.6 (65.6 to 85.5) 72.7 (49.8 to 89.3) 86.6 (76.6 to 93.7) 91.2	(71.5 to 100) 100 (29.2 to 100) 100 (93.8 to 100) 100 (98.5 to 100) -	(90.0 to 100) 66.7 (34.9 to 90.1) 89.8 (84.2 to 94.0) 94.4 (91.3 to 96.6)

There were no adverse events associated with this study.

MALES

158